the aid library

Filter

842

Download

View PDF

HIV and AIDS in Latin America the Caribbean regional overview

AVERT (2018) C2

Download

View PDF

Handbook on using the ECDC preparedness checklist tool to strengthen preparedness against communication disease outbreaks at migrant reception/detention centres

European Centre for Disease Prevention and Control (2016) C1

The checklist tool described in this handbook is intended for EU/EEA public health authorities who need to assess the capacity for communicable disease prevention and control at migrant reception/detention centres hosting migrants for weeks/months (medium-term) in order to identify gaps and set prio ... more

Download

View PDF

Philippine National Drug Formulary - Essential Medicines List, Volume I (7th Edition)

The National Formulary Committee, National Drug Policy, DOH Philippines (2008) C1

Download

View PDF

Welttuberkulosetag 2016: Gemeinsam gegen Tuberkulose

Robert Koch Institut (2016) C1

Epidemiologisches Bulletin; 14. März 2016 Nr. 10/11 ;DOI 10.17886/EpiBull-2016-014

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

When the Drugs Don’t Work – Antibiotic Resistance as a Global Development Problem

The Dag Hammarskjöld Foundation and ReAct (2019) C2

This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ... more

Download

View PDF

Africa CDC Non Communicable Diseases, Injuries Prevention and Control and Mental Health Promotion Strategy
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

Non-communicable diseases (NCDs) & injuries and mental health conditions constitute a serious impediment to achieving the vision of Agenda 2063 to build an integrated, prosperous, and peaceful Africa driven by its own citizens. Each year, these conditions cause millions of premature deaths and disab ... more

Download

View PDF

UNODC-WHO Stop-Overdose-Safely (‎S-O-S)‎ project implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine

World Health Organization WHO; United Nations Office on Drugs and Crime UNODC (2021) C_WHO

Summary Report

Download

View PDF

COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection

Anaya-Covarrubias, J.Y.; et al. (2022) C1

Curr Opin Pharmacol . 2022 Apr;63:102203.doi: 10.1016/j.coph.2022.102203. Epub 2022 Feb 11. The COVID-19 pandemic has widespread economic and social effects on Latin America (LA) and the Caribbean (CA). This region, which has a high prevalence of chronic diseases, has been one of the most affected ... more

Download

View PDF

ECOSOC Meeting “Addressing noncommunicable diseases and mental health: major challenges to sustainable development in the 21st century”

World Health Organization (2009) C_WHO

Discussion Paper "Mental health, poverty and development", July 2009

Download

View PDF

Standard treatment guidelines neurology (India)

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Download

View PDF

WHO Report on the Global Tobacco Epidemic, 2019. Offering help to quit tobacco use

World Health Organization WHO (2019) C_WHO

The seventh WHO Report on the global tobacco epidemic analyses national efforts to implement the most effective measures from the WHO Framework Convention on Tobacco Control (WHO FCTC) that are proven to reduce demand for tobacco. The report showed that while only 23 countries have implemented ce ... more

Download

View PDF

PAHO’s Health Emergency Appeal 2023

World Health Organisation (WHO) (2023) C_WHO

This document outlines PAHO’s regional priorities for the year 2023 to sustain and scale up health emergency and humanitarian assistance in the Americas, with a focus on five priority countries currently facing a prolonged humanitarian crisis and recovering from recent acute emergencies: Colombia, ... more

Download

View PDF

Expert and stakeholder virtual consultation meeting to develop the Africa CDC Non-Communicable Diseases and Mental Health Strategy

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C_CDC

Executive summary On 27th and 28th April 2021, the division of Disease Control and Prevention in collaboration with Public Health England, organized a virtual consultative meeting as part of the consultations with Member States and partners for the development of the Africa CDC five years strategic ... more

Download

View PDF

Protect the Progress: Rise, Refocus, Recover - 2020 Progress Report on the Every Woman Every Child Global Strategy for Women’s, Children’s and Adolescents’ Health (2016–2030)

UNICEF, World Health Organisation (2020) C_WHO

Conflict, climate crisis and COVID-19 pose great threats to the health of women and children.

Download

View PDF

WHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions

World Health Organisation (WHO) (2023) C_WHO

The overall objective of the framework is to support WHO and Members States in meaningful engagement of people living with NCDs, and mental health and neurological conditions to co-create and enhance related policies, programmes and services. This framework will contribute to advancing understanding ... more